{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"97.50","value":"0.0"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"52.18","value":"0.0"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"60.24","value":"0.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"description":"ORR was assessed for participants with MM using response criteria per International Myeloma Working Group (IMWG).\n\nORR was defined as the percentage of participants who experienced either one of the following based on investigator assessment:\n\n* partial response (PR)\n* very good partial response (VGPR)\n* complete response (CR)\n* stringent complete response (sCR)","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with RR MM and/or NHL received 80 mg AMG 397 QD2, as part of a 28-day treatment cycle.\n\nParticipants could receive AMG 397 until the participant became intolerant to the investigational product, signs and symptoms of clinical progression were evident as determined by the investigator, or the participant withdrew consent.","id":"OG000","title":"Part 1a: 80 mg AMG 397"},{"description":"Participants with RR MM and/or NHL received 160 mg AMG 397 QD2, as part of a 28-day treatment cycle.\n\nParticipants could receive AMG 397 until the participant became intolerant to the investigational product, signs and symptoms of clinical progression were evident as determined by the investigator, or the participant withdrew consent.","id":"OG001","title":"Part 1a: 160 mg AMG 397"},{"description":"Participants with RR MM received 320 mg AMG 397 QD2, as part of a 28-day treatment cycle.\n\nParticipants could receive AMG 397 until the participant became intolerant to the investigational product, signs and symptoms of clinical progression were evident as determined by the investigator, or the participant withdrew consent.","id":"OG002","title":"Part 1a: 320 mg AMG 397"}],"paramType":"NUMBER","populationDescription":"Parts 2 and 3 were not initiated and did not enrol any participants, therefore results presented only included participants in part 1. Participants with MM were only enrolled in part 1a, so therefore data is only presented for part 1a.\n\nFAS: All participants who were enrolled and received at least 1 dose of AMG 397.","reportingStatus":"POSTED","timeFrame":"Up to end of study (a maximum of 48 weeks)","title":"Overall Response Rate (ORR) for Participants With Multiple Myeloma (MM)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}